OMCL

Omnicell, Inc. Q2 2008 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2008. Omnicell, Inc. is a leading provider of medication control and patient safety solutions for acute care health facilities, primarily in the United States. The company operates in a single segment focused on medication and supply dispensing systems. As of June 30, 2008, the company employed 880 full-time employees, a 30.2% increase from the prior year.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 22.3% in Q2 2008 and 25.5% YTD compared to 2007, driven by increased installations of medication automation systems and new product features.
• Profitability Decline: Net income dropped significantly (84.8% in Q2, 70.6% YTD) primarily due to the absence of a $12.4 million income tax benefit recorded in the prior year from the release of a valuation allowance. The effective tax rate for the six months ended June 30, 2008, was 43.6%.
• Margin Pressure: Gross margins declined slightly (51.1% vs. 52.8% in Q2) due to the integration of lower-margin Rioux Vision mobile carts and costs associated with closing the Elgin, South Carolina manufacturing facility.
• Expense Increases: Operating expenses rose 20.2% in Q2, driven by a 32.2% increase in R&D and a 17.9% increase in SG&A, reflecting headcount growth and facility expansion.
• Capital Allocation: The company repurchased $65.1 million of common stock in the first six months of 2008, compared to a net cash inflow of $98.2 million from a secondary offering in the same period in 2007.

Outlook, Risks, and Unusual Items

• Acquisition Integration: The company is integrating Rioux Vision mobile cart technology with its medication control software. The first integrated version launched in June 2008. Goodwill was increased by $1.1 million in Q2 due to a refinement of estimates regarding pre-acquisition liabilities.
• Facility Closure: Omnicell announced the closure of its Elgin, SC facility, incurring approximately $0.3 million in costs in Q2, with remaining costs expected by September 2008.
• Legal Proceedings: The company is defending against product liability lawsuits (Alcala v. Cardinal Health; Takahama v. Torrance Memorial) and a patent infringement suit inherited from Rioux Vision (Flo Healthcare Solutions v. Rioux). Management intends to vigorously defend these claims.
• Guidance: Management expects gross margins to improve in the remainder of 2008 but noted they will fluctuate based on product mix and headcount. No specific numerical guidance for future quarters was provided in this text.
• Risks: Key risks include intense competition, dependence on a limited number of suppliers, potential delays in revenue recognition due to installation timelines, and the impact of tightening credit markets on customer financing.

Investor Verification Checklist

• Tax Rate Normalization: Verify the sustainability of the 43.6% effective tax rate and confirm the one-time nature of the prior year's tax benefit.
• Installation Backlog: Assess the timing of revenue recognition, as revenue is recognized upon installation, which can lag significantly behind orders.
• Margin Recovery: Monitor the impact of the Rioux Vision integration and facility closure costs on future gross margins.
• Legal Exposure: Review the status of the three active lawsuits (two product liability, one patent infringement) for potential financial impact.
• Stock Repurchase Program: Confirm the remaining balance of the authorized $50 million repurchase program announced in April 2008.